CORCEPT THERAPEUTICS I

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

06 5 2021 15:01:01 提供 Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

29 4 2021 15:05:01 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

15 3 2021 06:30:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer

01 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

23 2 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

08 2 2021 15:05:00 提供 Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

01 2 2021 15:05:00 提供 Nasdaq GlobeNewswire